Cary, NC–November 29, 2011–David C. Morgan has joined Calvert Holdings, Inc. as Director, Strategic Development, effective today. In this role, Mr. Morgan will assume responsibilities for new business initiatives the company plans to launch in the near term. Former Chief Banking Officer of Capital Bank, recently acquired by NAFH of Charlotte, NC. Mr. Morgan will report to Russ McLauchlan, Chairman and CEO of Calvert Holdings, Inc. and will be located in the company’s headquarters in Cary, North Carolina.

“I’ve known David for a number of years as a result of our outstanding relationship with the ownership and management of Capital Bank. Anyone knowing David would agree he possesses personal attributes critical to the success of any executive management team” noted Russ McLauchlan.  “I am particularly impressed with his personal drive and integrity, key characteristics we look for in our personnel.  David’s knowledge of the banking industry will be important to us as we continue to identify and enter business areas we have identified as a good fit for our portfolio. I couldn’t be happier he has agreed to be a part of Calvert and look forward to working with him as we continue to expand the business base of our operations.”

“Joining Calvert is a great opportunity for me, both personally and professionally. I have known Calvert for many years and have been impressed with the growth and entrepreneurial drive they exhibit” stated Mr. Morgan. He continued by adding, “Obviously, joining a company focused on drug development and high tech investment will bring its challenges, but I am confident my career experiences within the banking industry will help me make an immediate contribution to the growth of Calvert Holdings, Inc.  I am really excited to be a part of this team.”

Formed in 1996, Calvert Holdings, Inc. is a privately held company consisting of a diverse portfolio of companies including the following: Calvert Labs, Calvert Research, Calvert Corporate Funding, Carolina Securities, and Calvert Creative.

Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.

CARY, North Carolina-January 20, 2011–Underscoring its commitment to responsive customer service, Calvert Labs announced today that its newest communication tool, an iPhone application, has been released through Apple’s iTunes Store. In addition, the company has launched a secure, near real-time, info-on-demand section of its website.

This application marks the first release of this type of communication tool within preclinical CROs. Clients of Calvert Labs will have access to near real time, filtered information on demand.  This application provides clients with a time-saving way of reviewing study schedules and progressions, via updates that are pushed directly to the device. Clients will be able to contact study directors via phone or email directly from the app thus making communication easier and more efficient.

All features of the smartphone app are replicated within the secure private section of the website. This additional new product from Calvert allows clients without iPhones the opportunity to access information in a similar manner. Online communication with the app and the private section are encrypted with security provided by VeriSign.

“Because many people have grown accustomed to having 24/7 access to information on their smartphones, we decided to bring this technology into the hands of our clients,” noted Jeff Tippett of Calvert Creative (the sister company of Calvert Labs that created the app). He continued by adding: “We don’t want clients of Calvert Labs to wait for information. We want it available to them on demand.”

To learn how ease of access to information can help you, contact Jeff Tippett at jeff@calvertcreative.com.  The app is available immediately through the iTunes Store.

http://itunes.apple.com/us/app/calvert-labs/id406345642?mt=8

About Calvert Labs

Regarded by many as the premier IND-enabling contract research organization, Calvert Laboratories has been providing contract nonclinical services for almost four decades.  As a global service provider, Calvert Labs’ core offerings include toxicology (acute through chronic & carcinogenicity plus reproductive and developmental), pharmacokinetics & ADME, pharmacology, safety pharmacology, immunotoxicology and immunology.  Located in northeastern Pennsylvania and easily accessible by major airlines, Calvert Labs provides services to companies in the biotechnology, pharmaceutical, and chemical industrial sectors.

About Calvert Creative

Calvert Creative powers online and offline marketing by helping companies push their brand to the next level. Utilizing various marketing platforms, Calvert Creative develops strategies, executes campaigns, and optimizes results to reach the target market and drive traffic.

Cary, NC–November 11, 2010–Calvert Research, LLC announced today that one of the Company’s therapeutic development programs (T1-1081) qualified to receive federal grant funding totaling approximately $245,000 under the Patient Protection and Affordable Care Act of 2010 (“The ACT”), which will be used to help advance T1-1081 toward an IND application filing.

The Act created a $1.0 billion federal program to provide grants or tax credits to help support certain “Qualifying Therapeutic Discovery Projects” that have been designated by the Department of Health and Human Services using the following criteria: (a) the potential to create a novel therapy to treat unmet medical needs; (b) the potential to reduce long-term health care costs in the U.S., and (c) be among those projects with the greatest potential to create and sustain jobs and increase U.S. competitiveness.

T1-1081 is currently undergoing preclinical evaluation as a potentially more effective treatment for the wet form of Age-related Macular Degeneration (AMD), which is a major cause of significant vision loss in people over age 50 affecting millions worldwide.  T1-1081 was specifically designed to affect multiple factors that lead to vision loss by targeting and destroying unwanted blood vessels in the back of the eye that cause this disease, by blocking formation of new blood vessels, and by reducing inflammation that damages retinal cells.  T1-1081 also has the potential to treat other serious ocular diseases such as diabetic retinopathy, and the dry form of AMD

“We are very pleased to have been awarded the maximum amount from this competitive grant program, which will be used to help advance T1-1081 toward human clinical studies” said Dr. Michael A. Recny, President of Calvert Research.  “We licensed rights to develop and commercialize T1-1081 from Tulane University in 2009, and it represents a key component of our strategy to assemble a diverse portfolio of novel preclinical stage therapeutic compounds that we can advance quickly and efficiently toward human studies by leveraging our extensive in-house preclinical development expertise together with our preferred network of contract service partners”.

About Calvert Research

Commercial success in building the next generation of therapeutic drugs begins with identifying and acquiring the rights to the best potential drug candidates from top academic institutions and early stage biotechnology companies.  Calvert Research has long-established relationships with the leaders in over 160 academic technology transfer departments across North America and thousands of researchers at these institutions to source the best opportunities for investment.

Calvert Research designs a customized, integrated approach for each new drug candidate it acquired by utilizing senior scientists who have world-class experience in the design and submission of IND enabling preclinical development studies to regulatory agencies worldwide.  Since 2004, Calvert Research has invested in four preclinical stage therapeutic development programs, and to date has achieved three successful exits from selling or sublicensing rights to commercial partners, demonstrating a proven track record of success.

About Calvert Holdings, Inc.

Formed in 1996, Calvert Holdings, Inc. (www.calvertholdings.com) is a privately-held company consisting of a diverse portfolio of companies including Calvert Labs, Calvert Research, Calvert Corporate Funding, and Calvert Creative.

Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.

About Calvert Labs

As a global service provider, Calvert Labs’ core offerings include toxicology (acute through chronic & carcinogenicity plus reproductive and developmental), pharmacokinetics & ADME, pharmacology, safety pharmacology, immunotoxicology and immunology.

About Calvert Corporate Funding

Calvert Corporate Funding has emerged from its parent, Calvert Holdings, Inc., to address the needs of small and mid-sized companies seeking an alternative source of capital from traditional banking and lending institutions. Recent economic challenges, financial reform, and bank credit restrictions have created a need for viable options to be made available to business owners and operators.

In addition to its extensive network of non-bank lenders, Calvert Corporate Funding is a direct representative of the Global Finance Group, whose network includes a consortium of seventeen non-bank lenders. This array of investors specializes in lending to credit-worthy business owners/operators using creative financial packages.  Due to our extensive banking and asset-based lending experience, we are able to identify the optimum lender/company match.

About Calvert Creative
Calvert Creative powers online and offline marketing by helping companies push their brand to the next level. Utilizing various marketing platforms, Calvert Creative develops strategies, executes campaigns, and optimizes results to reach the target market and drive traffic.

Cary, NC September 22, 2010 — Calvert Holdings, Inc. today announced the launch of its newest business unit, Calvert Corporate Funding. Under the leadership of Andy Burch, this unit is formed to service the capital needs of small and mid-sized businesses looking to expand and grow market share.

“The rules for traditional sources of capital have changed in such dramatic fashion, that many businesses, mostly small companies or start-ups, are being shut out of credit facilities that in the past were readily available.

“After an extended review of credit needs of small and mid-sized businesses in the current financial environment, we were struck with the degree of difficulty many of these firms now have when seeking traditional financing tools necessary to maintain and grow their businesses,” noted Andy Burch. He continued by adding: “The rules for traditional sources of capital have changed in such dramatic fashion, that many businesses, mostly small companies or start-ups, are being shut out of credit facilities that in the past were readily available. We have teamed with the Global Finance Group, based in New York, to provide the link with non traditional lenders that may meet the financing needs of these small and mid-size businesses.”

“The addition of Calvert Corporate Financing fits squarely with our objective of portfolio diversification within Calvert Holdings. This new unit will add to the capabilities offered by our Carolina Securities, LLC, unit, which is best suited for companies interested in sale of their equity to private investors,” remarked Russ McLauchlan, CEO/Chair of the Board for Calvert Holdings, Inc. In commenting about Andy Burch’s role and expertise Mr. McLauchlan affirmed: “Andy Burch, a principal in Calvert Research, LLC and President of Carolina Securities, LLC, has a wealth of experience in dealing with lenders and companies seeking capital. As our business model develops, we expect Calvert Corporate Funding will be adding professional finance personnel to our group.”

Calvert Corporate Funding will focus its initial efforts on the North Carolina Triangle Region, but plans to expand throughout the Southeast within the next 12 months. The company will operate out of the Calvert Holdings corporate offices in Cary, NC.

About Calvert Holdings, Inc.
Calvert Holdings provides vision, resources and business leadership for all of the companies we develop and acquire. Life sciences are a core competency, but not all business endeavors are within that field. The Holdings is currently the parent company to Calvert Labs, Calvert Research, Calvert Corporate Funding, and Calvert Enterprises (Calvert Creative).
About Calvert Labs
Calvert Labs is a highly respected contract research organization specializing in the discovery and development of potential pharmaceuticals. In addition to lead identification and lead optimization services, we provide a wide array of preclinical services to help our clients navigate their GLP testing needs prior to advancing their discoveries into clinical trials.

About Calvert Research
Calvert Research is building the next generation of therapeutic drugs. Commercial success in this endeavor begins with identifying and acquiring the best potential drug candidates. Once licensed, Calvert Research rapidly and efficiently advances those assets to preclinical or clinical proof of concept, and delivers a valuable therapeutic to a development partner or acquirer.

About Calvert Enterprises
Calvert Enterprises is a testing ground for business endeavors outside of the life sciences. Currently within Enterprises is Calvert Creative.

Calvert Creative powers online and offline marketing by helping companies push their brand to the next level. Utilizing various marketing platforms, Calvert Creative develops strategies, executes campaigns, and optimizes results to reach the target market and ensure maximum lead generation.

###

Cary, North Carolina April 8, 2010 Calvert Holdings, Inc. announced today a restructuring of executive responsibilities within in its Calvert Research, LLC business unit, effective April 1^st, 2010.

Michael A. Recny, Ph.D. has been appointed as President of Calvert Research, LLC, assuming the position currently held by Russ McLauchlan, Chairman & Chief Executive Officer of Calvert Holdings, Inc.

“Michael and I have now worked together for several years, and I have come to appreciate that he is a highly competent individual who has a keen ability to balance his skills as an experienced scientist and successful drug developer with appropriate business insight and discipline” said Russ McLauchlan.  “Together we formed Calvert BioCapital, a new venture fund that would focus on acquiring and developing early stage drug candidates licensed from major universities.  While fundraising for the venture fund has now been terminated, we continue to believe the fundamental strategy we set is sound and viable. Our history of working with University technology transfer offices and young biopharmaceutical companies to develop and then identify clinical development partnerships gives us confidence our business model is sustainable. The changes in management responsibilities are designed to accelerate the pace of our portfolio development.”

Dr. Recny will be responsible for building an internal portfolio of clinical stage drug candidates within Calvert Research utilizing the same core elements of the investment strategy that he and Russ McLauchlan formulated in 2007.

“I am very pleased to assume this new leadership role within Calvert Research,” said Dr. Recny.  “We will continue to focus on implementing our capital efficient, virtual drug development model to create clinical stage assets that will be attractive acquisitions candidates for pharmaceutical and biotechnology partners.  Our current drug candidate  consists of a novel, patented compound we licensed from Tulane University in 2009 for the potential treatment of the wet form of age-related macular degeneration that is currently being evaluated in preclinical studies, and we look forward to expanding our portfolio with additional assets in the near future.”

Sam C. Tetlow, MBA will assume a new role as Vice President of Business Development for Calvert Research.  In this position, Mr. Tetlow will be instrumental in setting the strategic direction of the compounds and technologies housed within the Calvert Research portfolio while cultivating relationships with corporate partners interested in collaborating and acquiring rights to portfolio technologies as they advance toward human clinical trials.

“Sam first joined Calvert BioCapital shortly after we formed the fund, and we quickly learned that he improved our ability to interface with the investment community with his  operational and strong investment experience,” said Russ McLauchlan.  “In his new role within Calvert Research, Sam will be instrumental in helping to execute our business model, as well as contributing to other important business initiatives within Calvert Holdings, Inc.”

Andy Burch, Vice President of Calvert Research, will continue to lead the direct involvement of Calvert Research with University Technology Transfer offices and will add to his role as President of Carolina Securities LLC, a wholly owned business unit of Calvert Holdings, Inc. Mr. Burch will also assume additional responsibilities for new business initiatives within Calvert Holdings, Inc.  “Andy is a valued member of the Calvert organization and we look to him to drive the implementation of many initiatives we have put into our longer term strategic plan,” said Mr. McLauchlan. “We know that Andy has been key to our success in multiple sectors of our businesses, and we want to deploy his efforts across several other areas of our company.”

About Calvert Holdings, Inc.

Formed in 1996, Calvert Holdings, Inc. is a privately held company consisting of a diverse portfolio of companies including the following: Calvert Laboratories, Calvert Research, Calvert Creative, Carolina Securities, and Calvert Café & Catering.

Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.

CARY, North Carolina — Calvert Research LLC (a Calvert Holdings Inc. company) announced today the hiring of Dr. Dana Minnick as Director of Project Management.

Earning a PhD, MS, and BA from Case Western Reserve University in Cleveland, Ohio, Dr. Minnick pursued post-doctoral studies at the National Institute of Environmental Health Science, Research Triangle Park, NC. In 2006, Dr. Minnick received the GlaxoSmithKline Excellence in Science award.

Bringing almost a decade of pharmaceutical experience in preclinical drug discovery and development, Dr. Minnick stated: ” I am excited to be joining Calvert Research. I look forward to being a part of this talented team committed to bridging the gap between drug discovery and development.”

Established in early 2005 to work with early-stage companies to advance their lead candidate biopharmaceuticals, Calvert Research has further evolved to working closely with Technology Transfer executives of major universities across the country to identify, license, and develop novel biopharmaceutical compounds. Mr. Russ McLauchlan, CEO, noted: ” Dr. Minnick’s professional experiences fit perfectly into our organization. She brings the skills to advance our group’s capabilities as we continue to identify technologies we expect to license and develop and a personality that reflects our corporate image. We’re glad she has joined us and we all look forward to working with her. ”

Formed in 1996, Calvert Holdings, Inc. is a privately-held company consisting of a diverse portfolio of companies including the following: Calvert Labs, Calvert Research, Calvert BioCapital, Calvert Creative, Carolina Securities, and Calvert Cafe.

Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.

CARY, North Carolina — Calvert Research LLC (a Calvert Holdings Inc. company) and Auburn University announced today a joint research project entitled, Targeted Drug Delivery. Undertaken through Auburn University College of Veterinary Medicine’s Department of Pathobiology, the six-month study is under the direction of Dr. Valery Petrenko. Dr. Lonnie Bookbinder, west coast regional director, is coordinating the research on behalf of Calvert Research LLC.

The study will center on the hypothesis that targeting siRNA-containing pharmaceutical nanocarriers, such as liposomes, with breast tumor-specific phage proteins may significantly enhance their anti-cancer activity. “This particular study was selected after an extensive nationwide effort to research numerous potential delivery technologies,” stated Dr. Bookbinder. He continued by adding: “Calvert Research LLC looks forward to advancing science through this partnership with Auburn University and Dr. Petrenko.”

“I am very pleased to collaborate with Calvert,” Dr. Petrenko said. “Their experts first recognized that the merging of phage nanobiotechnology developed at Auburn with genomics can contribute vigorously to different areas of medicine, specifically in the area of targeted cancer therapy. I believe the new concept of phage-driven drug-delivery, which we explore in our partnership program, will demonstrate its power and vitality in the near future.”

“This is an exciting opportunity for Auburn to contribute to the advancement of drug delivery technologies. This partnership with Calvert Research represents another example of how our college is working with Auburn’s Office of Technology Transfer to market our faculty’s discoveries,” said Dr. Timothy R. Boosinger, dean.

“The Auburn project fits our plans to invest in novel therapeutic approaches that will advance clinical development of new drug compounds. We share the belief that future pharmaceuticals and biologicals will have targeted delivery,” explained Russ McLauchlan, CEO of Calvert Holdings Inc. “Our alliance with Auburn University gives us a position in this growing field.”

Scheduled to conclude in April 2009, the study’s results will be published by Auburn University.

About Calvert Research LLC
Calvert Research Institute was formed to bridge the gap in the early-stage drug and device development cycle. The group has implemented an innovative model of strategic partnering and can utilize the virtual nature of a consortium of specialized companies and services so that investment communities and start-ups both achieve their goals.

About Auburn University
For more news about Auburn University, visit http://wireeagle.auburn.edu/. In-depth reporting, including multimedia features and downloadable photographs for media use, can be found at http://www.ocm.auburn.edu/newsmakers/. Auburn University has provided instruction, research, and outreach to benefit the state and nation for more than 150 years, and is among a distinctive group of universities designated as Land, Sea, and Space Grant institutions. Auburn makes a nearly $5 billion economic contribution to the state each year, has more than 250,000 graduates, and provides 130 degree programs to more than 24,000 graduate and undergraduate students.

About Calvert Holdings Inc.
Formed in 1996, Calvert Holdings, Inc. (www.calvertholdings.com) is a privately-held company consisting of a diverse portfolio of companies including the following: Calvert Labs, Calvert Research, Calvert BioCapital, Calvert Creative, Carolina Securities, and Calvert Cafe.

Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.

CARY, North Carolina — Calvert Creative (a Calvert Holdings, Inc. company) announced today that Lisa Creech Bledsoe will be the keynote speaker for an upcoming global webinar sponsored by Cisco Systems, Inc. entitled: Connected Women. The webinar, slated for September 25, 2008, will focus on leadership with an emphasis on how collaboration works and how it works best.

Daneen West, Manager Learning and Development for Cisco Systems, commented: “Cisco’s Connected Women is a global initiative to create unique, compelling events, for senior female decision makers across various industries. It establishes and cultivated the network of professional women across different internet/innovative industries.” She continued by adding: “The objective of Connected Women is to network with peers as well as to stimulate thought on how the workplace is changing and the corresponding impact this will have on ways of working, and skill-sets required in the workforce.”

Calvert Creative specializes in training companies to use cutting-edge, online communication tools. As early adopters of new communication techniques, Calvert Creative helps businesses adopt innovative practices for business-to-business and business-to-consumer communication.

Registration for the seminar is free and information is available by contacting Lisa Creech Bledsoe at 919.854.4453 or lisa@calvertcreative.com.

CARY, North Carolina — Calvert Creative (a Calvert Holdings, Inc. company) announced today plans to conduct a seminar entitled, “What is Social Media? How Can it Move Business” in conjunction with the Downtown Raleigh Alliance.

The seminar, slated for September 10 at 10:00AM, is designed to introduce businesses to social media and to begin discussions of how this new marketing may be used to move businesses. Sequential seminars are part of the overall strategy. The event, hosted by Long View Center in downtown Raleigh, is free to the public.

Many executives have noticed the upsurge in publicity about social media including recent buzz about it in the presidential elections. Now companies are saying we need to understand social media and become participants, reported Jeff Tippett, the Outreach Strategist for Calvert Creative’s parent company: Calvert Holdings, Inc. Many companies have determined that being dark in the social media realm is no longer a viable option. They have to find ways to be participants in order to manage their online branding as well as to understand their competition’s online presence.

The seminar is designed to offer an entry-level understanding of social media and to engage businesses in collaboration about implementing social media as part of their overall strategy for online communication.

Information about the upcoming seminar is available by contacting Lisa Creech Bledsoe at 919.854.4453 or lisa@calvertcreative.com.

Cary, North Carolina — Calvert Holdings, Inc. is currently recruiting a Data Architect for immediate hire. The successful candidate will be responsible to manage the flow of data, administrate systems within the corporate office, and coordinate the construction and ongoing management of all web properties. Preference will be given to candidates that have been involved with start up organizations. Resumes will be accepted until a successful candidate is secured.

Please send resumes to jobs@calvertholdings.com